首页|177Lu标记HER2亲和体的制备及性能研究

177Lu标记HER2亲和体的制备及性能研究

Preparation and properties of 177Lu-labeled HER2 affibody

扫码查看
目的 制备一种177 Lu标记的人表皮生长因子受体2(HER2)亲和体177Lu-1,4,7-三氮杂环壬烷-1,4,7-三乙酸(NOTA)-马来酰亚胺(Mal)-半胱氨酸(Cys)-ZHER2;342(简称177 Lu-NOTA-MZHER2),探讨其标记工艺及抗肿瘤性能.方法 考察2种缓冲液体系(乙酸钠缓冲液体系和抗坏血酸钠缓冲液体系),比较pH值、前体质量与反应温度对177Lu标记NOTA-MZHER2的影响,获取最佳标记条件.采用快速薄层色谱(ITLC)测定标记产物放化纯,观察其在PBS和血浆中的稳定性.取人源性卵巢癌细胞SKOV-3进行细胞内化和细胞毒性实验,评价177Lu-NOTA-MZHER2的细胞摄取和杀伤效果.取SKOV-3荷瘤鼠(n=3)注射177Lu-NOTA-MZHER2后进行microSPECT/CT显像.另取荷瘤鼠40只,分为尾静脉注射探针22.2 MBq(静注22.2 MBq)组、对照组(尾静脉注射PBS)、低剂量组(瘤体注射探针3.7 MBq)和高剂量组(瘤体注射探针7.4 MBq),每组10只,注射探针后监测肿瘤体积和荷瘤鼠体质量,评估标记产物的抗肿瘤效应和毒性.采用重复测量方差分析(Bonferroni法)比较数据间的差异.结果 乙酸钠缓冲液体系下,pH=4、前体质量50μg、70~80℃反应30 min,为最优标记条件.在此条件下,标记产物177Lu-NOTA-MZHER2的标记率为(99.3±0.4)%,放化纯>99%;在PBS和血浆中放置12 d后,放化纯分别为(95.0±1.5)%和(95.0±2.1)%.细胞实验结果显示,177Lu-NOTA-MZHER2的细胞内化占总摄取的(29.02±3.50)%,在标记产物放射性浓度为6×10-3 Bq/L时,SKOV-3细胞的存活率为(48±6)%.SPECT显像示,注射 18.5 MBq 177Lu-NOTA-MZHER2后96h,该药仍在肿瘤部位浓聚.静注22.2 MBq组、高剂量组、低剂量组与对照组比较,荷瘤鼠的相对肿瘤体积(RTV)差异有统计学意义(F=21.75,P<0.001);高剂量组注射后20 d,荷瘤鼠RTV为(140±7)%,相对体质量为(80±9)%,与对照组相比,具有明显的抗肿瘤效果(均P<0.001).结论 成功制备177Lu-NOTA-MZHER2,工艺简单高效,该药具有较好的抗肿瘤效果.
Objective To prepare a 177Lu labeled human epidermal growth factor receptor 2(HER2)affibody 177Lu-1,4,7-triazacyclononane-1,4,7-triacetic acid(NOTA)-maleimide(Mal)-cysteine(Cys)-ZHER2:342(1n Lu-NOTA-MZHER2 for short),and investigate its labeling process and anti-tumor properties.Methods Two kinds of buffer systems(sodium acetate buffer system and sodium ascorbate buffer system)were investigated.The effects of pH value,precursor mass and reaction temperature on 177Lu labe-ling NOTA-MZHER2 were compared to obtain optimal labeling conditions.The radiochemical purity of la-beled product was determined by instant thin-layer chromatography(ITLC),and its stabilities in PBS and plasma were observed.Human ovarian cancer cell line SKOV-3 was selected for cell internalization and cyto-toxicity test to evaluate cell uptake and killing effect of 177Lu-NOTA-MZHER2.SKOV-3 tumor-bearing mice(n=3)were injected with 177Lu-NOTA-MZHER2,and microSPECT/CT imaging was performed.Another 40 tumor-bearing mice were divided into 22.2 MBq group(tail vein injection with probe of 22.2 MBq),control group(tail vein injection with PBS),low-dose group(tumor injection with probe of 3.7 MBq)and high-dose group(tumor injection with probe of 7.4 MBq).Tumor volume and mass of tumor-bearing mice were monitored after injection,and the anti-tumor effect and toxicity of probe were evaluated.Repeated measure-ment analysis of variance(Bonferroni method)was used to analyze the data.Results The optimal labeling condition was 70-80 ℃ for 30 min in the system of sodium acetate buffer solution with pH=4 and precursor mass of 50 μg.Under these conditions,the labeling rate of 177Lu-NOTA-MZHER2 was(99.3±0.4)%and radiochemical purity was>99%.After 12 d in PBS and plasma,the radiochemical purities were(95.0±1.5)%and(95.0±2.1)%.Results of cell experiment showed that the internalization of 177Lu-NOTA-MZHER2 accounted for(29.02±3.50)%of the total uptake,and the survival rate of SKOV-3 cells was(48±6)%with the probe concerntration of 6×10-3 Bq/L.SPECT imaging showed that 177Lu-NOTA-MZHER2 was still concentrated at the tumor site 96 h after injection with a dose of 18.5 MBq.Relative tumor volume(RTV)of tumor-bearing mice in 22.2 MBq group,high-dose group and low-dose group was significantly dif-ferent from that in control group(F=21.75,P<0.001).Twenty days after injection,RTV and relative body mass of the tumor-bearing mice in high-dose group were(140±7)%and(80±9)%,respectively.Compared with control group,high-dose group had obvious anti-tumor effect(both P<0.001).Conclusion 177Lu-NOTA-MZHER2 is successfully prepared,which is simple and efficient,and the probe has good anti-tumor effect.

Ovarian neoplasmsGenes,erbB-2Isotope labelingLutetiumTumor cells,cul-turedRadionuclide imagingMice,nude

国洪霞、潘栋辉、宿晨、徐宇平、王立振、严骏杰、王辛宇、陈重阳、杨慧、杨敏

展开 >

内蒙古医科大学药学院,呼和浩特 010110

国家卫生健康委员会核医学重点实验室、江苏省分子核医学重点实验室、江苏省原子医学研究所,无锡 214063

卵巢肿瘤 基因,erbB-2 同位素标记 肿瘤细胞,培养的 放射性核素显像 小鼠,裸

江苏省自然科学基金江苏省自然科学基金内蒙古自治区高等学校科研项目

BK20192005BK20231141NJZY21591

2024

中华核医学与分子影像杂志
中华医学会

中华核医学与分子影像杂志

CSTPCD北大核心
影响因子:1.107
ISSN:2095-2848
年,卷(期):2024.44(6)